RxDoctor Payments Data

Cheridah Seeley, PA

Family Medicine · Quartz Hill, CANPI 1659571024

Payments from drug & device makers

$9,428in general payments, 2019–2025

Across 307 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$840
  • AbbVie$544
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,428 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$11,102
Medicare patients
76
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$46,839
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,598
LinzessLinaclotide18$22,689
JardianceEmpagliflozin16$14,056
KerendiaFinerenone14$12,127
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$6,130
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,942
PaxlovidNirmatrelvir/Ritonavir11$4,122
Humalog Kwikpen U-100Insulin Lispro14$3,727
Aripiprazole22$3,584
Varenicline Tartrate12$3,146
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen85$2,421
Albuterol Sulfate HfaAlbuterol Sulfate75$2,097
Donepezil Hcl35$1,143
Cyclobenzaprine Hcl39$991

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,141$46,83940 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,212$36,53959 claims
AbbVieLinzess$544$22,68918 claims
Boehringer IngelheimJardiance$840$14,05616 claims
BayerKerendia$130$12,12714 claims
PfizerPaxlovid$118$4,12211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Quartz Hill

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →